Skip to main content

Parachute mitral valve and supramitral ring

 


Parachute mitral valve and supramitral ring are both rare congenital anomalies of the mitral valve apparatus, often associated with left-sided obstructive lesions and sometimes coexisting as part of Shone’s complex. They share the common feature of producing left atrioventricular inflow obstruction, but their anatomical basis and clinical implications differ.


Parachute mitral valve is characterized by the insertion of all, or most, of the chordae tendineae into a single papillary muscle instead of the normal two. In some cases, there may be two papillary muscles present but one is underdeveloped and functionally all chordae converge to the dominant one. This abnormal arrangement causes restricted opening of the mitral valve leaflets, leading to varying degrees of mitral inflow obstruction. The severity of obstruction depends on the degree of chordal crowding and leaflet tethering. Clinically, parachute mitral valve can manifest in childhood with symptoms of pulmonary congestion, dyspnea, and sometimes failure to thrive, but in mild cases it may remain asymptomatic until adulthood. It is frequently associated with other left-sided obstructive lesions such as coarctation of the aorta and supravalvular mitral ring, forming part of the Shone’s complex.


Supramitral ring, sometimes referred to as supravalvular mitral ring, is a ridge or shelf of fibrous or fibromuscular tissue located in the left atrium just above the mitral valve annulus. This ring can partially or completely encircle the mitral orifice and may adhere to the mitral leaflets. Depending on its extent and thickness, it can significantly obstruct blood flow from the left atrium to the left ventricle. Unlike the parachute mitral valve, the pathology lies above the annulus and not in the subvalvular apparatus. Clinically, patients present with features similar to mitral stenosis, including exertional dyspnea, pulmonary venous hypertension, and recurrent respiratory infections in childhood. In severe cases, the supramitral ring can mimic rheumatic mitral stenosis, but the congenital origin and younger age at presentation help distinguish it.


Both conditions are diagnosed by echocardiography, which clearly delineates the site of obstruction and the associated anomalies. Management depends on the severity of obstruction and clinical symptoms. In symptomatic patients with significant obstruction, surgical intervention may be required. In parachute mitral valve, surgery involves mobilization of chordae or splitting of the papillary muscle, whereas in supramitral ring, excision of the obstructive ridge is performed. Prognosis depends on the severity of the obstruction and the presence of associated cardiac anomalies.



Comments

  1. Great post about cardiac care! Sundaram Medical Foundation, the best multispeciality hospital in anna nagar and mogappair, Chennai, provides professional cardiologists and cutting-edge amenities. Highly recommended for heart health screenings and treatment!

    ReplyDelete

Post a Comment

Drop your thoughts here, we would love to hear from you

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...